For example, in the PARADIGM-HF trial, which evaluated the effects of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with HFrEF, NT-proBNP levels increased in patients receiving the therapy, despite significant reductions in HF hospitalizations and mortality [100]. This evidence concerns the gene NPPB and hydrops fetalis.